Astec Lifesciences Limited (ASTEC) AI Stock Analysis

Astec Lifesciences Limited

(NSE:ASTEC)

Select Model

Rating:52Neutral

Price Target:INR 552.00▲(0.46% Upside)

Action:reiterated

Date:09/23/26

The stock's overall score is heavily weighed down by severe fundamental distress, primarily driven by chronic unprofitability, alarming cash burn, and a highly unattractive valuation. While technical indicators demonstrate strong recent bullish price action, the underlying operational weakness presents substantial structural risks.

Positive Factors

Agrochemical product breadthAstec participates across several crop-protection product stages and applications, supplying both active ingredients and intermediates alongside select formulations. This operating base gives the company relevance across insecticide, herbicide, and fungicide demand and supports a durable position in agricultural inputs.

Negative Factors

Sustained large lossesAstec's shift from positive profits in FY22–FY23 to sizable losses through FY26 shows that revenue recovery has not yet translated into economic profitability. Persistent negative operating profit can weaken reinvestment capacity, reduce financial flexibility, and make a durable earnings recovery more difficult.

Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.19B
Dividend Yield: ―
Average Volume (3M): 11.00K
Price to Earnings (P/E): -15.4
Beta (1Y): 1.27
Revenue Growth: 16.06%
EPS Growth: 36.97%
Country: India
Employees: 471
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the co...

Astec Lifesciences Limited Financial Statement Overview

Summary

Severe financial distress dominates the company's profile. Despite a recent 18.5% revenue rebound and improved debt-to-equity ratios, deep core unprofitability and a massive negative operating cash flow of 1.12 billion raise substantial liquidity concerns.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	4.41B	4.48B	3.81B	4.58B	6.28B	6.77B
Gross Profit	552.59M	419.01M	-685.16M	1.33B	2.27B	2.86B
EBITDA	89.92M	-15.49M	-662.07M	-2.69M	893.14M	1.65B
Net Income	-665.97M	-809.17M	-1.35B	-469.30M	255.65M	898.59M
Balance Sheet
Total Assets	0	9.42B	8.81B	9.75B	9.79B	8.97B
Cash, Cash Equivalents and Short-Term Investments	100.49M	122.51M	8.55M	16.47M	27.54M	33.44M
Total Debt	0	4.49B	5.55B	4.94B	3.41B	2.79B
Total Liabilities	-3.91B	5.51B	6.46B	6.05B	5.60B	5.00B
Stockholders Equity	3.91B	3.91B	2.35B	3.69B	4.19B	3.96B
Cash Flow
Free Cash Flow	-234.96M	-1.18B	-302.20M	-1.25B	-426.03M	-803.74M
Operating Cash Flow	-199.52M	-1.13B	-83.99M	102.21M	746.56M	236.04M
Investing Cash Flow	-73.41M	-49.07M	-152.30M	-1.35B	-1.13B	-1.04B
Financing Cash Flow	297.62M	1.27B	237.33M	1.25B	377.70M	804.77M

Astec Lifesciences Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price549.45

Price Trends

50DMA665.51Negative

100DMA675.13Negative

200DMA664.58Negative

Market Momentum

MACD-31.99Positive

RSI27.08Positive

STOCH5.37Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 549.45 is below the 20-day moving average (MA) of 675.59, below the 50-day MA of 665.51, and below the 200-day MA of 664.58, indicating a bearish trend. The MACD of -31.99 indicates Positive momentum. The RSI at 27.08 is Positive, neither overbought nor oversold. The STOCH value of 5.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ASTEC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SHARDACROP	79Outperform	INR 59.96B	9.88	―	2.20%	17.28%	42.45%
IN:BHARATRAS	74Outperform	INR 15.49B	6.96	―	0.05%	-5.17%	4.24%
IN:DHANUKA	73Outperform	INR 43.75B	16.33	―	0.21%	-5.63%	-11.38%
IN:INSECTICID	66Neutral	INR 15.10B	12.23	―	0.37%	1.26%	-16.43%
IN:IPL	66Neutral	INR 12.97B	12.54	―	0.64%	17.05%	9.10%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ASTEC	52Neutral	INR 12.18B	-15.36	―	―	16.06%	36.97%

* General Sector Average

Performance Comparison

IN:ASTEC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ASTEC	Astec Lifesciences Limited	549.45	-114.40	-17.23%
IN:BHARATRAS	Bharat Rasayan Limited	944.10	-1825.51	-65.91%
IN:DHANUKA	Dhanuka Agritech Limited	959.05	-354.27	-26.98%
IN:INSECTICID	Insecticides (India) Limited	536.65	-180.42	-25.16%
IN:IPL	India Pesticides Ltd.	117.30	-67.26	-36.44%
IN:SHARDACROP	Sharda Cropchem Ltd.	683.25	-114.36	-14.34%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 23, 2026

Astec Lifesciences Limited AI Stock Analysis